Table 4.
Positive NAb onset incidence per treatment cycle for onabotulinumtoxinA across all 10 indications.
| Treatment Cycle | Number of Patients with Positive NAb for the First Time | Total Number of Patients Receiving OnabotulinumtoxinA a | Incidence of Positive NAb Onset (%) [95% CI] |
|---|---|---|---|
| 1 | 6 | 4278 | 0.1 [0, 0.3] |
| 2 | 5 | 2959 | 0.2 [0, 0.3] |
| 3 | 0 | 2584 | 0 |
| 4 | 3 | 1624 | 0.2 [0, 0.4] |
| 5 | 2 | 1001 | 0.2 [0, 0.5] |
| 6 | 5 | 610 | 0.8 [0.1, 1.5] |
| 7 | 1 | 422 | 0.2 [0, 0.7] |
| 8 | 4 | 334 | 1.2 [0, 2.4] |
| 9 | 1 | 259 | 0.4 [0, 1.1] |
| 10 | 0 | 176 | 0 |
| 11 | 0 | 116 | 0 |
| 12 | 0 | 49 | 0 |
| 13 | 0 | 17 | 0 |
| 14 | 0 | 6 | 0 |
| 15 | 0 | 1 | 0 |
NAb, neutralizing antibody. a Number of patients who had evaluable immunogenicity data and had not yet developed positive NAbs up to that treatment cycle. Not all patients had NAb results for every treatment cycle.